Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
http://izea.me/2xw7Dql
Amazing
Moving to IZEA
Augmented Sponsorship™ leverages the ARKit technology in Apple’s newly
released iOS 11, which is optimized for iPhone 8 and iPhone X, and available
for all iPhones 6s and greater . ARKit simplifies the placement of virtual 3D
objects and animations in real-world environments.
http://izea.me/2xw7Dql
Teaming up with VERI= $12+
VERI/QTM connection should run Quantum stock imo.
NVDA, ITUS and VERI best AI stocks for rapid growth imo. Arificial intelligence in chips, cancer detection and computing=high growth rates and pe ratios. See charts on all three.
ITUS and VERI continue to impress in artificial intelligence, Both in major areas of growth with just 15m shares outstanding, Charts bullish with upward trendlines.
VERI and ITUS continue to impress in artificial intelligence, Both in major areas of growth with just 15m shares outstanding, Charts bullish with upward trendlines.
ITUS now a pure play in Artificial intelligence just like VERI. Both are my favorite plays in thsi space. See chart on VERI, ITUS just starting.
My Pure Plays in AI are VERI and ITUS. VERI is computer to computer and ITUS with new patent in AI for cancer detection. Both with huge futures.
Charts say $2.50-$2.75
Back to $38-$45
NVDA could acquire VERI to lead in Artificial Intelligence for years to come.
FB could buy VERI to take Lead in Artificial Intelligence.
AMZN could buy VERI to lead Artificial Intelligence
This means bigger than AMZN or FB.
Leading artificial intelligence firms' market cap is going to "absolutely, positively" represent five to 10 times the market cap of today's consumer internet and social media giants, Breyer Capital CEO Jim Breyer said at CNBC and Institutional Investor's Delivering Alpha conference in New York on Tuesday, Sept. 12.
YY remains top stock in growth and pe. Goldman initiates with $101 target and that imo is CONSERVATIVE.
If PFE buys AVXL, I buy PFE and if BIIB buys AVXL, I buy BIIB. Will be a winner for years for whomever owns AVXL.
Imo future is bright and blockchain is like the internet in early stages. These shorts will be longs if they want to make the big money.
Trade if you must but I am buying MGTI for the bigger future it holds.
If PFE buys AVXL, I buy PFE and if BIIB buys AVXL, I buy BIIB. Will be a winner for years for whomever owns AVXL.
PFE new Annual High. AVXL related?
Re: Important Points
#2 This is the reason for adding funds. The further we go into trials alone the more data they have and more worldwide bids AVXL receives.
To all those guessing when trails will start i say, who cares, they will start when they can. Remember PK PD data needs to be provided first.
The reason why we fell in JUly is because those investors expected trials to start in July and attend a conference in London, stop the guessing and become investors or go buy a 1 year CD at a bank ! Yes they have a conference on Monday but I think its just preclinical data and October 30 is a conference on PD data. All steps forward to human trials. Each day we get closer but too many want to time exactly when LOL. They will be left buying higher or not at all.
Important Points:
1) Missling knows what they have more than we at this time.
2) The further we go into human trials in AD, PD and Rett, the more BP will need to pay.
3) Remember AD is worldwide disease, offers for AVXL will also be worldwide.
4) These CNS diseases have low bars to beat for FDA approval. No treatment for Rett, only 3 months of stabilizing AD with DPZ. Anavex already reports at least 12 month stability.
5) Imo. if Rett shows any improvement in patients we get approval. I think the drug would sell at $300,000/year per patient. If you only treat a portion of the population its a 3 BILLION DOLLAR drug.
6) Worst case scenario, in AD the drug shows only better sleep without sedation in AD and Dementia patients. With little or no side effects already established. Thats a 10 BILLION DOLLAR drug.
7) Our government alone would save trillions in health care costs if Anavex shows lengthening AD stabilitity, not curing, just stability for 12 months. ( all Missling needs to do is tweet Trump, he will have Missling at his home the next day !)
I like GBTC and ENVV.
$10 soon.
$2+ soon. Caveat emptor lifted and company says all financials up to date with sec.
Sept 11th CNS Conference: ANAVEX 2-73, a Sigma-1 Receptor Agonist, Targeting Neurodegenerative and Neurodevelopmental Diseases
Daniel Klamer Daniel Klamer
Vice President, Business Development & Scientific Strategy
Anavex Life Sciences
Abstract:
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical stage biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders. Anavex’s lead candidate, ANAVEX 2-73, is an orally available compound that restores cellular homeostasis by targeting Sigma-1 and muscarinic receptors. ANAVEX 2-73, has demonstrated good safety, bioavailability, and tolerability in Phase 1 and Phase 2 clinical trials. In addition, data from an ongoing Phase 2a clinical trial in Alzheimer’s Disease demonstrates dose dependent cognitive improvements. The compound also exhibits anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat a broad range of CNS disorders.
ANAVEX 2-73 significantly improves multiple behavioral phenotypes in the Rett Syndrome mouse model in a dose-related manner. Based on these data, Anavex Life Sciences will start a U.S. multicenter Phase 2 clinical trial of ANAVEX 2-73 for the treatment of Rett Syndrome with the support of Rettsyndrome.org.
The Michael J. Fox Foundation for Parkinson’s Research awarded Anavex Life Sciences a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s Disease. Ongoing preclinical research in this therapeutic area demonstrates that ANAVEX 2-73 ameliorates motor deficits in spontaneous rotational activity and forelimb use asymmetry, and exerts significant neurorestorative effects on the damaged nigrostriatal dopamine system.
The scientific rationale, preclinical data, and clinical development path of ANAVEX 2-73 as a novel treatment strategy for Rett Syndrome, Parkinson’s Disease, and Multiple Sclerosis will be discussed in more detail. This presentation will explore the links between preclinical findings and clinical trial development trajectory in our ongoing translational research efforts.
(So imo, since this is a partership/deal conference,MJFF for Parkinsons trial and Rett Organzation for Rett trial, even to speak about MS has me wondering if they have a MS deal. Thoughts?)
When BITCF reopens, MGTi flies too imo.
Goldman Sachs INITIATES with $101 PT today.
CNS market far larger than KITE market. AVXL jumps on high volume will be headlines imo.
Very welcome for KITE, I now recommend AVXL.
MGTI in major business of preventing hacking at server level for homes and business, privacy phones that will be safer for all of us and cryptocurrency and blockchain innovation which is the future.
KITE buyout causes my target for AVXL now @ $75-$115 depending on what metric used as compared to KITE.
I TOLD EVERYONE>AVXL IS NEXT, BUY.
I posted earlier KITE and AVXL my favorites, AVXL is next.
CNBC reports the average dementia patient costs 322,000 dollars and to expect to pay 70% of that figure yourself. Government needs to approve AVXL NOW !
It doesn't need to be released by then but I do think it will be soon. Trail designs were waiting for that info. What I am excited about also is the Lund University study in PD over there in Sweden, I think this leads to human trials and a HUGE potential. MS now being talked about by Anavex is saying all symptoms are go. This reminds me of when I bought KITE at lows too !
Sept 11th CNS Conference: ANAVEX 2-73, a Sigma-1 Receptor Agonist, Targeting Neurodegenerative and Neurodevelopmental Diseases
Daniel Klamer Daniel Klamer
Vice President, Business Development & Scientific Strategy
Anavex Life Sciences
Abstract:
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical stage biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders. Anavex’s lead candidate, ANAVEX 2-73, is an orally available compound that restores cellular homeostasis by targeting Sigma-1 and muscarinic receptors. ANAVEX 2-73, has demonstrated good safety, bioavailability, and tolerability in Phase 1 and Phase 2 clinical trials. In addition, data from an ongoing Phase 2a clinical trial in Alzheimer’s Disease demonstrates dose dependent cognitive improvements. The compound also exhibits anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat a broad range of CNS disorders.
ANAVEX 2-73 significantly improves multiple behavioral phenotypes in the Rett Syndrome mouse model in a dose-related manner. Based on these data, Anavex Life Sciences will start a U.S. multicenter Phase 2 clinical trial of ANAVEX 2-73 for the treatment of Rett Syndrome with the support of Rettsyndrome.org.
The Michael J. Fox Foundation for Parkinson’s Research awarded Anavex Life Sciences a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s Disease. Ongoing preclinical research in this therapeutic area demonstrates that ANAVEX 2-73 ameliorates motor deficits in spontaneous rotational activity and forelimb use asymmetry, and exerts significant neurorestorative effects on the damaged nigrostriatal dopamine system.
The scientific rationale, preclinical data, and clinical development path of ANAVEX 2-73 as a novel treatment strategy for Rett Syndrome, Parkinson’s Disease, and Multiple Sclerosis will be discussed in more detail. This presentation will explore the links between preclinical findings and clinical trial development trajectory in our ongoing translational research efforts.
(So imo, since this is a partership/deal conference,MJFF for Parkinsons trial and Rett Organzation for Rett trial, even to speak about MS has me wondering if they have a MS deal. Thoughts?)